Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Conditions
Keywords
Futibatinib, Advanced cholangiocarcinoma, cholangiocarcinoma, FGFR2, Fusion, Rearrangemen, TAS-120
Brief summary
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Detailed description
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. Eligible patients will be randomized on a 1:1 basis to the following study arms: * Patients will receive futibatinib at an oral dose of 16 mg, administered daily (QD) on every day of a 21-day cycle. * Patients will receive futibatinib at an oral dose of 20 mg, administered daily (QD) on every day of a 21-day cycle. Patients may continue to receive continuous futibatinib until documentation of progressive disease (PD) per RECIST 1.1, or until other withdrawal criteria are met, whichever comes first.
Interventions
DRUGTAS-120
TAS-120 is an oral FGFR inhibitor
Sponsors
Taiho Oncology, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed, locally advanced, metastatic, or unresectable intrahepatic of extrahepatic Cholangiocarcinoma. 2. Documented evidence of FGFR2 gene fusions or other FGFR2 rearrangement 3. Received at least one prior systemic gemcitabine and platinum-based regimen for CCA 4. Documentation of radiographic disease progression on the most recent prior therapy 5. Measurable disease 6. performance status 0 or 1 7. Adequate organ function
Exclusion criteria
1. History or current evidence of calcium and phosphate homeostasis disorder 2. Current evidence of clinically significant retinal disorder 3. Treatment with any of the following within the specified time frame prior to the first dose of futibatinib: 1. Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of futibatinib) and radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks 2. Patients with locoregional therapy, eg, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks 3. Any non investigational anticancer therapy within 3 weeks or have not recovered from side effects of such therapy prior to futibatinib. Endocrine therapy is allowed for patients with breast or prostate cancer 4. Targeted therapy or immunotherapy within 3 weeks or within 5 half lives Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter. 5. Patients with prior FGFR-directed therapy 4. A serious illness or medical condition(s) including (but not limited to) the following: 1. Known brain metastasis (not including primary brain tumors) unless patient is clinically stable for ≥1 month 2. Known acute systemic infection 3. Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (New York Heart Association \[NYHA\] Class III or IV New York Heart Association \[NYHA\] Classification) within the previous 2 months; if \>2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms 4. Significant gastrointestinal disorder(s) that could interfere with the absorption of futibatinib. 5. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study. 5. Known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment. 6. Pregnant or lactating female. 7. Known hypersensitivity or severe reaction to futibatinib or its excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR by independent central review | 12 months after the study completion | defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on ICR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS by independent review | up to 12 months after the study completion | defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first |
| ORR per Investigator assessment | up to 12 months after the study completion | defined as proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST v1.1). |
| DoR per Investigator assessment | up to 12 months after the study completion | defined as time from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurs first |
| PFS per Investigator assessment | up to 12 months after the study completion | defined as the time from date of randomization to the date of disease progression based on Investigator assessment of radiographic images or death, whichever occurs first |
| DoR by independent review | up to 12 months after the study completion | defined as time from the first documentation of response to the first documentation of objective tumor progression by ICR (per RECIST 1.1) or death due to any cause, whichever occurs first |
| Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 | up to 12 months after the study completion | Safety will be assessed based on reported AEs (including SAEs), graded by CTCAE V5.0. including serious adverse events (SAEs) and dose modifications. |
| Change from Baseline in Quality of life as assessed by EORTC QLQ-C30 | up to 12 months after the study completion | Change from Baseline in quality of life as assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score |
| Change from Baseline in Quality of life as assessed by EuroQol-5D (EQ-5D ) | up to 12 months after the study completion | Change from Baseline in Quality of Life as Assessed by European Quality of Life - 5 Dimensions-3 Levels (EQ-5D-3L) Scale Score. |
| OS | up to 12 months after the study completion | defined as the time from the date of randomization until the date of death due to any cause. |
Countries
Argentina, Australia, Brazil, Canada, China, Hong Kong, Italy, Japan, Poland, Portugal, South Korea, Spain, United States
Contacts
Primary ContactTaiho Oncology, INC
Outcome results
None listed